Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
I Karniadakis, N Mazonakis, C Tsioutis… - Infectious Disease …, 2023 - mdpi.com
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S Ombelet, D Castanares‐Zapatero… - Journal of medical …, 2024 - Wiley Online Library
Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …
Impact factors of Blastocystis hominis infection in persons living with human immunodeficiency virus: a large-scale, multi-center observational study from China
SX Zhang, JC Wang, ZW Li, JX Zheng, WT Zhou… - Infectious Diseases of …, 2023 - Springer
Abstract Background Blastocystis hominis (Bh) is zoonotic parasitic pathogen with a high
prevalent globally, causing opportunistic infections and diarrhea disease. Human …
prevalent globally, causing opportunistic infections and diarrhea disease. Human …
Nirmatrelvir/ritonavir use and hospitalizations or death in a previously uninfected nonhospitalized high-risk population with COVID-19: a matched cohort study
AA Butt, P Yan, OS Shaikh, VB Talisa… - The Journal of …, 2024 - academic.oup.com
Objective To determine the association of nirmatrelvir/ritonavir (NMV/r) with hospitalization
or death within 30 days as compared with untreated controls previously uninfected and …
or death within 30 days as compared with untreated controls previously uninfected and …
[HTML][HTML] Characteristics and outcome of a territory-wide cohort study of patients with acquired hemophilia A in Hong Kong
C Sin, THS Li, K Wong, K Wong, Y Sin, WK Lam… - Thrombosis …, 2024 - Elsevier
Abstract Introduction Acquired hemophilia A (AHA) is a rare bleeding disorder with
destruction of factor VIII by autoantibodies. Comprehensive data for Chinese patients are …
destruction of factor VIII by autoantibodies. Comprehensive data for Chinese patients are …
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study
M Rinaldi, C Campoli, M Gallo, D Marzolla… - BMC infectious …, 2023 - Springer
Purpose To investigate the clinical impact of three available antivirals for early COVID-19
treatment in a large real-life cohort. Methods Between January and October 2022 all …
treatment in a large real-life cohort. Methods Between January and October 2022 all …
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
X Zhong, C Wang, L Huang, Y Zhao, T Li… - Frontiers in …, 2023 - frontiersin.org
Background: The breakthrough development of novel severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) vaccines and oral antivirals have played a critical role in …
coronavirus-2 (SARS-CoV-2) vaccines and oral antivirals have played a critical role in …
OPEN ACCESS EDITED BY
A Saffaei, I Education, H Yousefian… - The Evolution in …, 2024 - books.google.com
Tylosin belongs to the macrolide family of antibiotics, which share a macrocyclic lactone ring
structure critical for their antibacterial activity (Arsic et al., 2018). Variations in this ring …
structure critical for their antibacterial activity (Arsic et al., 2018). Variations in this ring …
SARS-CoV-2 індуковані зміни кишкової мікробіоти та імунометаболізму лімфоцитів у хворих на цукровий діабет 2 типу
ПВ ПЕТАХ - 2023 - repository.tdmu.edu.ua
У дисертації вперше встановлено особливості змін кишкової мікробіоти у пацієнтів із
COVID-19 та цукровим діабетом 2-го типу (ЦД-2), котрі приймали метформін або …
COVID-19 та цукровим діабетом 2-го типу (ЦД-2), котрі приймали метформін або …